- Pharma giants are navigating U.S. President Donald Trump’s demands to bring U.S. drug prices in line with other developed nations.
- Eli Lilly’s decision to hike Mounjaro prices in the U.K. could spark similar moves from other firms, analysts say.
- The U.S. consistently pays the most in the world for many prescription drugs.
Eli Lilly’s move to raise the U.K. list price of its blockbuster diabetes drug Mounjaro marks the start of prices hikes across Europe, analysts say, as pharmaceutical firms respond to U.S. President Donald Trump’s drug pricing demands.
Lilly said Thursday that it had reached an agreement with the U.K. government to raise the list price of its weekly injection from Sept. 1, while maintaining access for patients covered by the publicly funded National Health Service (NHS).
The U.S. pharma giant said it is now working with some other governments to adjust prices by the start of next month, without providing details of the specific countries involved. Analysts expect other firms to follow suit.
Source: https://www.cnbc.com/2025/08/18/eli-lilly-pharma-firms-to-hike-prices-on-trumps-drug-pricing-demands.html